Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.92 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.92 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HLA-A | P04439 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxazosin SCHEMBL29359735 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL29429099 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL2945426 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL4725733 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL42621 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL17652050 | 0.98 | KMT2A (0.95) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL10549641 | 0.97 | KMT2A (0.94) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL10416953 | 0.96 | KMT2A (0.93) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL1648487 | 0.96 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL29711371 | 0.96 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017139487-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | NORTHWIND MEDICAL, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-2432458-A2 | INGESTIBLE EVENT MARKERS COMPRISING AN INGESTIBLE COMPONENT | Proteus Biomedical, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2427178-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | Laboratory Skin Care, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120059257-A1 | Ingestible Event Markers Comprising an Ingestible Component | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110189239-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110105864-A1 | Pharma-Informatics System | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | disclosed |